A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
一项针对复发风险高的胰腺腺癌切除术后患者的随机、II期临床试验,研究口服阿扎胞苷(CC-486)的疗效。
期刊:Clinical Epigenetics
影响因子:4.4
doi:10.1186/s13148-022-01367-8
Heumann, Thatcher R; Baretti, Marina; Sugar, Elizabeth A; Durham, Jennifer N; Linden, Sheila; Lopez-Vidal, Tamara Y; Leatherman, James; Cope, Leslie; Sharma, Anup; Weekes, Colin D; O'Dwyer, Peter J; Reiss, Kim A; Monga, Dulabh K; Ahuja, Nita; Azad, Nilofer S